Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Chemiluminescence Immunoassay Market analysis

The France Chemiluminescence Immunoassay Market was valued at $488.2 Million in 2026 and projected to reach to $691 Million by 2031, representing a compound annual growth rate of 7.2%. France's chemiluminescence immunoassay market is poised for sustained growth through 2031, supported by increasing healthcare expenditure and modernization of diagnostic facilities across the country.

France Chemiluminescence Immunoassay Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Chemiluminescence Immunoassay Market Trends and Insights

  • France's healthcare sector continues to invest in advanced diagnostic technologies, positioning the country as a key player in the European immunoassay landscape.
  • The growth trajectory in France is driven by increasing demand for rapid, accurate diagnostic solutions across clinical laboratories and hospital networks. France's market expansion is supported by robust healthcare infrastructure and regulatory frameworks that encourage adoption of innovative diagnostic platforms.
  • Between 2026 and 2031, France is anticipated to experience steady market penetration as healthcare providers prioritize automation and efficiency in laboratory operations.
  • The French market benefits from strong pharmaceutical and diagnostics manufacturing capabilities, which reinforce the region's competitive advantage in chemiluminescence immunoassay technologies..

Key Market Statistics

  • CAGR (2026-2031) 7.2% CAGR
  • Market Size, 2026 ~USD 488.2 Million
  • Forecast, 2031 ~USD 691 Million
  • Country France

France Chemiluminescence Immunoassay Market Overview

Market Valuation Growth :

France's chemiluminescence immunoassay market is valued at USD 488.2 million in 2026 and is projected to reach USD 691.0 million by 2031, demonstrating robust expansion in the country's diagnostic sector.

Consistent CAGR Performance :

The French market maintains a steady compound annual growth rate of 7.2% through 2031, aligning with global market trends and reflecting sustained demand for advanced immunoassay technologies.

Healthcare Investment Focus :

France's healthcare sector continues to prioritize investments in advanced diagnostic technologies, strengthening the country's position as a key player in the European immunoassay landscape.

European Market Leadership :

As a major European economy with sophisticated healthcare infrastructure, France drives innovation and adoption of chemiluminescence immunoassay systems across the continent.

France Chemiluminescence Immunoassay Market Dynamics

  • The French healthcare system's emphasis on precision medicine and early disease detection creates favorable conditions for immunoassay technology adoption.
  • Hospital networks and diagnostic laboratories in France are actively upgrading their capabilities to meet evolving clinical demands. The market expansion is further bolstered by France's strong regulatory framework, which ensures quality standards and encourages investment in advanced diagnostic solutions.
  • Collaborations between French healthcare institutions and diagnostic manufacturers are expected to accelerate innovation and market penetration.
  • The country's aging population and rising prevalence of chronic diseases will continue to drive demand for reliable and efficient immunoassay platforms..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • France's chemiluminescence immunoassay market reaches USD 488.2 million in 2026 and grows to USD 691.0 million by 2031 at a 7.2% CAGR.
    • France's advanced healthcare infrastructure and regulatory environment support steady adoption of automated diagnostic solutions.
    • France's strong diagnostics manufacturing base positions the country as a regional hub for immunoassay technology innovation.
    • France's market growth is driven by clinical laboratories and hospitals seeking improved diagnostic efficiency and accuracy between 2026 and 2031.

    Chemiluminescence Immunoassay Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment ONCOLOGY (Application)
    Forecast Period 2026–2031
    Growth Rate CAGR of 7.2% from 2026 to 2031
    Largest Segment CONSUMABLES (Product Type)
    Market Size Base Year (Billions) ~USD 11.58 (2026)
    Revenue Forecast (Billions) ~USD 16.39 (2031)
    Segments Covered Product Type, Technology, Sample Type, Application, End User

    France Chemiluminescence Immunoassay Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product Type

    • Consumables
    • Instruments

    By Technology

    • Chemiluminescence Enzyme Immunoassays (Cleia)
    • Electrochemiluminescence Immunoassays (Ecli)
    • Microparticle Chemiluminescence Immunoassays

    By Sample Type

    • Blood
    • Other Sample Types
    • Saliva
    • Urine

    By Application

    • Allergy Diagnostics
    • Autoimmune Disorders
    • Blood Screening
    • Bone & Mineral Disorders
    • Cardiology
    • Endocrinology
    • Gastroenterology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Newborn Screening
    • Oncology
    • Other Applications
    • Respiratory Diseases
    • Therapeutic Drug Monitoring
    • Toxicology

    By End User

    • Clinical Laboratories
    • Hospitals
    • Other End Users
    • Pharmaceutical & Biotechnology Companies And Cros

    FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    CLINICAL LABORATORIES163.6172.7183194.4207221236.5253.86.8
    HOSPITALS257.8273.1290.4309.5330.7354.3380.5409.67.1
    OTHER END USERS55.458.161.164.46872.176.681.66
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS53.456.259.462.966.77175.7816.4
    TOTAL530.3560.2593.9631.2672.4718.5769.48266.8

    Target Audience

    • Diagnostic Equipment Manufacturers : Manufacturers need France-specific market data to assess market potential, identify growth opportunities, and develop localized product strategies for the French healthcare system.
    • Healthcare Facility Operators : Hospital networks and diagnostic laboratories in France require market insights to make informed capital investment decisions regarding immunoassay system upgrades and procurement.
    • Medical Device Distributors : Distributors operating in France need detailed market forecasts and competitive intelligence to optimize inventory management, pricing strategies, and sales planning for the French market.
    • Healthcare Investors & Consultants : Investment firms and management consultants require France-specific market data to evaluate investment opportunities, conduct due diligence, and provide strategic recommendations to healthcare clients.
    • Regulatory & Policy Advisors : Healthcare policy experts and regulatory consultants need market insights to understand France's diagnostic sector dynamics and inform healthcare policy recommendations and compliance strategies.

    Key Companies in the France Chemiluminescence Immunoassay Market

    CompanyHQOwnershipStrongest segments
    ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
    SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction solutions),Life Sciences (instruments, genomics, and research tools),Diagnostics (clinical instruments and consumables),
    DIASORIN S.P.A.ItalyPublic CompanyLIAISON XL / LIAISON XS immunodiagnostics,Molecular diagnostics (Simplexa, congenital CMV, LIAISON PLEX assays),xMAP technology platform and related IVD solutions,
    QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Point of Care,Transfusion Medicine,
    SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers & reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems & reagents,Blood gas / electrolyte / urinalysis,
    SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.ChinaPublic CompanyImmunoassay analyzers and reagents,Biochemistry/Electrolyte systems and reagents,Integrated systems and lab automation,
    TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls, PVC chain, and petrochemicals (VCM, ethylene, propylene, aromatics),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia, beads),
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Consumables,Informatics and Software,
    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.ChinaPublic CompanyPatient monitoring & life support (incl. ventilators, anesthesia, defibrillation, infusion),Ultrasound & medical imaging (incl. radiology, emergency ultrasound, endoscope camera systems),In-vitro diagnostics (CLIA, chemistry, hematology),

    ABBOTT

    Abbott is a United States-based public company founded in 1888 with 115,000 employees, operating in the healthcare and pharmaceutical sectors.

    SIEMENS HEALTHINEERS AG

    Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating across diversified industrial and life sciences sectors.

    DIASORIN S.P.A.

    DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees engaged in in vitro diagnostics and molecular diagnostics.

    QUIDELORTHO CORPORATION

    QuidelOrtho Corporation is a United States-based public company founded in 1979 with 6,500 employees specializing in diagnostic solutions.

    SYSMEX CORPORATION

    Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees focused on in vitro diagnostics and hematology systems.

    SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.

    Shenzhen New Industries Biomedical Engineering Co., Ltd. is a Chinese public company founded in 1995 with 2,785 employees operating in the biomedical diagnostics sector.

    TOSOH CORPORATION

    Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees engaged in specialty chemicals and diagnostics.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees providing life science research and clinical diagnostics products.

    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

    Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a Chinese public company founded in 1991 with 21,288 employees manufacturing medical devices and diagnostics equipment.

    Reasons to Buy this Report

    • France-Specific Market Sizing : Obtain precise valuation data for France's chemiluminescence immunoassay market with detailed 2026-2031 forecasts, enabling accurate business planning and investment decisions tailored to the French market.
    • Competitive Landscape Intelligence : Understand the competitive dynamics specific to France's diagnostic sector, including key players, market share distribution, and strategic positioning within the French healthcare ecosystem.
    • Growth Driver Analysis : Identify France-specific factors driving the 7.2% CAGR, including healthcare policy changes, technological adoption rates, and regulatory developments unique to the French market.
    • Regional Expansion Strategy : Develop targeted market entry or expansion strategies for France by leveraging country-specific insights on healthcare infrastructure, reimbursement models, and customer preferences.
    • Investment & Partnership Opportunities : Identify high-potential investment and partnership opportunities within France's growing diagnostic sector, supported by detailed market segmentation and opportunity assessment.

    Frequently asked questions

    What is the market size of chemiluminescence immunoassay in France?

    France's chemiluminescence immunoassay market is valued at USD 488.2 million in 2026 and is projected to reach USD 691.0 million by 2031.

    What is the growth rate of the chemiluminescence immunoassay market in France?

    France's chemiluminescence immunoassay market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2031.

    What factors drive market growth in France?

    France's market growth is driven by increasing demand for rapid diagnostic solutions, investment in healthcare infrastructure, automation in clinical laboratories, and strong regulatory support for innovative diagnostic technologies.

    Which sectors in France are adopting chemiluminescence immunoassay?

    France's clinical laboratories, hospital networks, and diagnostic centers are the primary adopters of chemiluminescence immunoassay technologies for improved diagnostic efficiency.

    How does France compare to other European markets?

    France benefits from advanced healthcare infrastructure, strong diagnostics manufacturing capabilities, and robust regulatory frameworks that position it as a key player in the European chemiluminescence immunoassay market.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the CLIA market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and companies' SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the CLIA market. It was also used to obtain important information on key players, market classification, and segmentation aligned with industry trends to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after secondary research provided information on the CLIA market. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific,  Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief Executive Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, and product development/innovation teams, as well as related key executives from manufacturers and distributors operating in the CLIA market.; and key opinion leaders.

    Primary interviews were conducted to gather insights into market statistics, revenue from products and services, market breakdowns, market size estimates, market forecasting, and data triangulation. Primary research also helped in understanding the various trends in technology, applications, verticals, and regions. Stakeholders from the demand side, customers/end users who are using infection control products, were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.

    The following is a breakdown of the primary respondents:

    Chemiluminescence Immunoassay Market Size, and Share

    Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
    Note 2: Other primaries include sales managers, marketing managers, and product managers.
    Note 3: Companies are classified into tiers based on their total revenue.
    As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the CLIA market includes the following details.

    The market sizing was conducted on a global basis.

    Country-level Analysis: The size of the CLIA market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall CLIA market was obtained from secondary data and validated by primary participants to arrive at the total CLIA market. Primary participants further validated the numbers.

    Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

    Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
    Approach 2: Geographic adoption trends for individual product segments by end user and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

    At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall CLIA market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

    Global Chemiluminescence Immunoassay Market : Top-Down and Bottom-Up Approach

    Chemiluminescence Immunoassay Market Top Down and Bottom Up Approach

    Data Triangulation

    The market was split into several segments and subsegments after determining the overall market size, using the market sizing processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for each market segment and subsegment. The data was triangulated by examining various factors and trends on both the demand and supply sides of the CLIA market.

    Market Definition

    Chemiluminescent immunoassay (CLIA) is an immunoassay technique in which the label, i.e., the indicator of the analytical reaction, is a luminescent molecule. CLIA is a variation of the standard enzyme immunoassay (EIA), a biochemical technique used in immunology. This variation technique can be used for medical diagnosis and in several other industries for various applications. In recent years, CLIA has attracted increasing attention across fields such as clinical diagnosis, life sciences, food safety, environmental monitoring, and pharmaceutical analysis, due to its high specificity, high sensitivity, broad applicability, simple instrumentation, and wide linear range.

    Key Stakeholders

    • CLIA manufacturers and distributors
    • CLIA analyzers & consumables manufacturers
    • Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies)
    • Healthcare institutions (hospitals and outpatient clinics)
    • Distributors and suppliers
    • Research institutes
    • Health insurance payers
    • World Health Organization (WHO)
    • Organisation for Economic Co-operation and Development (OECD)
    • National Institutes of Health (NIH)
    • Centers for Disease Control and Prevention (CDC)
    • Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
    • White Papers, Journals/Magazines, and News Articles
    • Paid Databases, such as Factiva, D&B Hoovers, and Bloomberg Business

    Report Objectives

    • To define, describe, segment, and forecast the global CLIA market by product type, technology, sample type, application, end user, and region.
    • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall CLIA market.
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
    • To forecast the size of the CLIA market in five main regions, along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile key players in the global CLIA market and comprehensively analyze their core competencies and market shares.
    • To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
    • To benchmark players within the CLIA market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

    Available customizations:

    Based on the given market data, MarketsandMarkets offers customizations tailored to the company’s specific needs. The following customization options are available for the report:

    Geographic Analysis

    • Further breakdown of the Rest of Asia Pacific CLIA market into Thailand, Indonesia, Philippines, Vietnam, Hong Kong, and other countries
    • Further breakdown of the Rest of Europe CLIA market into Belgium, Russia, the Netherlands, Switzerland, and other countries.
    • Further breakdown of the Rest of Latin America CLIA market into Argentina, Peru, and other countries.

     

    Get the Full Chemiluminescence Immunoassay Market Report

    Full forecast, segment splits, and company analysis for all Chemiluminescence Immunoassay Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status